The story noted that aspirin is sold for pennies a pill. The printer version of the story reports only relative risk reductions, ignoring the important point that most colorectal cancer patients in this study survived for many years whether or not they took aspirin after their diagnosis; thus it exaggerates the potential benefits of adding aspirin to the treatment mix. Specifically, the story discussed whether aspirin should get credit for “beating cancer,” although there is nothing in the study about aspirin being a cure. To put the results in context, the story should have mentioned that the 10-year survival rates were 69 percent for those not taking aspirin and 74 percent for those who did take aspirin. (PLEASE NOTE:  ABSOLUTE RISK REDUCTION FIGURES APPEARED IN A WEB VERSION OF THE SIDEBAR BUT WE CURRENTLY REVIEW ONLY WHAT APPEARS IN PRINT.) PLEASE NOTE:  WE MISSED THE FACT THAT A SIDEBAR TO THE MAIN STORY DID INCLUDE INFORMATION ON GASTROINTESTINAL BLEEDING. SO WE HAVE CHANGED THIS GRADE TO SATISFACTORY. The story includes several caveats warning that the results of the study are not definitive. It pointed out some of the limitations inherent in this sort of observational study. It also pointed out that a randomized controlled trial would be needed in order to actually prove that aspirin fights cancer. However, the story highlighted the sharply lower rate of colorectal disease deaths among patients who had a type of colorectal cancer that overproduces the COX-2 enzyme and took aspirin after diagnosis… without mentioning either the wide uncertainty in the number or that the overwhelming majority of patients survived for many years, whether or not they took aspirin. (PLEASE NOTE:  THIS INFORMATION DID NOT MAKE IT INTO THE PRINT VERSION BUT WAS INCLUDED IN AN ONLINE VERSION OF THE STORY.) The story did not discuss the prevalence or consequences of colorectal cancer, so we judge this criterion to be not applicable in this case. While the story included a quote from a physician who was not connected to the study and even though this study was funded by public money, the story failed to explain what expertise the independent source has or why his opinion was relied upon. Nonetheless, we give this story the benefit of the doubt on this criterion. This story does not mention that the overwhelming majority of patients receiving standard therapy for colorectal cancer survive for many years, thus hyping the potential benefits of aspirin. (THE ABSOLUTE RISK REDUCTION FIGURES DID NOT APPEAR IN THE PRINT VERSION OF THE STORY BUT DID APPEAR IN AN ONLINE VERSION. WE CURRENTLY REVIEW ONLY WHAT APPEARS IN PRINT.) Aspirin is widely available. However, the study focused on the COX-2 inhibitory action of aspirin and the authors suggested that rather than aspirin becoming a standard part of colon cancer treatment, future treatment might rely on a drug specifically designed to use this pathway to fight cancer. By using the term ‘revolutionary’ to describe the study results, this story ignores the many years of research into the potentially beneficial effects of aspirin on colorectal cancer. The story included a physician not connected with the study and the reporter apparently interviewed one of the study authors. So it clearly did not rely solely or largely on a news release.
‘Revolutionary’ use for aspirin? May help colon cancer patients